(Q37913119)

25 August 2017

1 reference

title

Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics (English)

1 reference

25 August 2017

1 reference

Brosen K

1

1 reference

25 August 2017

publication date

1 March 1990

1 reference

Clinical Pharmacokinetics

25 August 2017

published in

1 reference

25 August 2017

volume

18

1 reference

25 August 2017

issue

3

1 reference

25 August 2017

page(s)

220-239

1 reference

Debrisoquine-type polymorphism of drug oxidation: purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation

25 August 2017

cites work

1 reference

12 December 2020

Defective N-oxidation of sparteine in man: A new pharmacogenetic defect

1 reference

12 December 2020

Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4.

1 reference

12 December 2020

A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquin

1 reference

12 December 2020

Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type II.

1 reference

12 December 2020

Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism

1 reference

12 December 2020

Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22.

1 reference

12 December 2020

Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics

1 reference

12 December 2020

Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism

1 reference

12 December 2020

Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamine

1 reference

12 December 2020

Polymorphic oxidation of sparteine and debrisoquine: Related pharmacogenetic entities

1 reference

12 December 2020

Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22.

1 reference

12 December 2020

The debrisoquine hydroxylation test predicts steady-state plasma levels of desipramine

1 reference

12 December 2020

Polymorphism of carbon oxidation of drugs and clinical implications

1 reference

12 December 2020

Inhibitors of the microsomal oxidation of psychotropic drugs: selectivity and clinical significance

1 reference

12 December 2020

Enantioselectivity of 4-hydroxylation in extensive and poor metabolizers of debrisoquine

1 reference

12 December 2020

Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences

1 reference

12 December 2020

The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine

1 reference

12 December 2020

The molecular mechanisms of two common polymorphisms of drug oxidation--evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation

1 reference

12 December 2020

Low frequency of slow debrisoquine hydroxylation in a native Chinese population

1 reference

12 December 2020

Drug Interaction: Inhibitory Effect of Neuroleptics on Metabolism of Tricyclic Antidepressants in Man

1 reference

12 December 2020

The P450 superfamily: updated listing of all genes and recommended nomenclature for the chromosomal loci

1 reference

12 December 2020

Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites

1 reference

12 December 2020

Identification of an inducible form of cytochrome P-450 in human liver

1 reference

12 December 2020

In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver

1 reference

12 December 2020

Metoprolol and debrisoquin metabolism in Nigerians: lack of evidence for polymorphic oxidation

1 reference

12 December 2020

Is there a genetic factor in flecainide toxicity?

1 reference

12 December 2020

High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation

1 reference

12 December 2020

Sparteine oxidation polymorphism: a family study

1 reference

12 December 2020

Debrisoquine/sparteine-type polymorphism of drug oxidation. Purification and characterization of two functionally different human liver cytochrome P-450 isozymes involved in impaired hydroxylation of the prototype substrate bufuralol

1 reference

12 December 2020

Pharmacokinetics of N-propylajmaline in relation to polymorphic sparteine oxidation

1 reference

12 December 2020

Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype.

1 reference

12 December 2020

E- and Z-10-hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation

1 reference

12 December 2020

Nortriptyline and antipyrine clearance in relation to debrisoquine hydroxylation in man

1 reference

12 December 2020

Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes

1 reference

12 December 2020

Substantial rise in sparteine metabolic ratio during haloperidol treatment

1 reference

12 December 2020

Influence of the defective metabolism of sparteine on its pharmacokinetics

1 reference

12 December 2020

The influence of enzyme induction on polymorphic sparteine oxidation

1 reference

12 December 2020

Evolution of cytochrome P-450 proteins.

1 reference

12 December 2020

First-pass metabolism of imipramine in man

1 reference

12 December 2020

Relationship between dose and plateau levels of drugs eliminated by parallel first-order and capacity-limited kinetics

1 reference

12 December 2020

Sparteine oxidation is practically abolished in quinidine-treated patients

1 reference

12 December 2020

Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation.

1 reference

12 December 2020

Characterization of the common genetic defect in humans deficient in debrisoquine metabolism

1 reference

12 December 2020

Steady-state kinetics of imipramine in patients

1 reference

12 December 2020

Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype

1 reference

12 December 2020

Pharmacokinetics and metabolism of quinidine in extensive and poor metabolisers of sparteine

1 reference

12 December 2020

Steady-state plasma levels of E- and Z-10-OH-nortriptyline in nortriptyline-treated patients: significance of concurrent medication and the sparteine oxidation phenotype.

1 reference

12 December 2020

Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI)

1 reference

12 December 2020

Cyclosporin-erythromycin interaction in normal subjects.

1 reference

12 December 2020

Substrate specificity of human liver cytochrome P-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling

1 reference

12 December 2020

The P450 gene superfamily: recommended nomenclature

1 reference

12 December 2020

Correlation between nortriptyline and debrisoquine hydroxylation in the human liver

1 reference

12 December 2020

Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism

1 reference

12 December 2020

Oxidative metabolism of hexobarbital in human liver: relationship to polymorphic S-mephenytoin 4-hydroxylation

1 reference

12 December 2020

Quinidine inhibits the 2-hydroxylation of imipramine and desipramine but not the demethylation of imipramine

1 reference

12 December 2020

Studies on the metabolism of perhexiline in man.

1 reference

12 December 2020

Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations

1 reference

12 December 2020

Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings

1 reference

12 December 2020

Metabolism of methoxyphenamine in extensive and poor metabolizers of debrisoquin

1 reference

12 December 2020

Discovery of altered pharmacokinetics of CGP 15 210 G in poor hydroxylators of debrisoquine during early drug development

1 reference

12 December 2020

Intestinal absorption, demethylation, and enterohepatic circulation of imipramine

1 reference

12 December 2020

Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man

1 reference

12 December 2020

Inhibition of desipramine 2-hydroxylation by quinidine and quinine

1 reference

12 December 2020

Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugs

1 reference

12 December 2020

Characterization of cDNAs, mRNAs, and proteins related to human liver microsomal cytochrome P-450 (S)-mephenytoin 4'-hydroxylase

1 reference

12 December 2020

Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man

1 reference

12 December 2020

Drug metabolism in human liver in vitro: establishment of a human liver bank.

1 reference

12 December 2020

Polymorphic debrisoquin hydroxylation in 757 Swedish subjects

1 reference

12 December 2020

In vitro metabolism of sparteine by human liver: competitive inhibition by debrisoquine

1 reference

12 December 2020

Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices

1 reference

12 December 2020

Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers

1 reference

12 December 2020

Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism)--increased Michaelis is Constant (Km) and loss of stereoselectivity of bufuralol 1'-hydroxylation in poor metabolizers

1 reference

12 December 2020

Drug interaction between propafenone and metoprolol

1 reference

12 December 2020

A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.

1 reference

12 December 2020

Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4.

1 reference

12 December 2020

Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes.

1 reference

12 December 2020

In vitro inhibition studies of two isozymes of human liver cytochrome P-450. Mephenytoin p-hydroxylase and sparteine monooxygenase

1 reference

12 December 2020

First-pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype

1 reference

12 December 2020

Oxidation of quinidine by human liver cytochrome P-450

1 reference

12 December 2020

Purification of a desmethylimipramine and debrisoquine hydroxylating cytochrome P-450 from human liver

1 reference

12 December 2020

Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers

1 reference

12 December 2020

Polymorphic hydroxylation of Debrisoquine in man.

1 reference

12 December 2020

Quinidine kinetics after a single oral dose in relation to the sparteine oxidation polymorphism in man.

1 reference

12 December 2020

Interindividual differences in amitriptyline demethylation

1 reference

12 December 2020

High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver

1 reference

12 December 2020

A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and is inducible by cigarette smoking

1 reference

12 December 2020

Mephenytoin-type polymorphism of drug oxidation: purification and characterization of a human liver cytochrome P-450 isozyme catalyzing microsomal mephenytoin hydroxylation

1 reference

12 December 2020

Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction

1 reference

12 December 2020

Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine

1 reference

12 December 2020

In vitro characterization of the human cytochrome P-450 involved in polymorphic oxidation of propafenone

1 reference

12 December 2020

Influence of oxidation polymorphism on phenformin kinetics and dynamics

1 reference

12 December 2020

Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism

1 reference

12 December 2020

Role of oxidation polymorphism on blood and urine concentrations of amitriptyline and its metabolites in man

1 reference

12 December 2020

Amitriptyline metabolism: relationship to polymorphic debrisoquine hydroxylation

1 reference

12 December 2020

Stereoselective mephobarbital hydroxylation cosegregates with mephenytoin hydroxylation

1 reference

12 December 2020

The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions

1 reference

12 December 2020

The relationship between imipramine metabolism and the sparteine oxidation polymorphism

1 reference

12 December 2020

Genetically determined oxidation capacity and the disposition of debrisoquine

1 reference

12 December 2020

Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs.

1 reference

12 December 2020

Relevance of genetic polymorphism in drug metabolism in the development of new drugs

1 reference

12 December 2020

Clinical significance of the sparteine/debrisoquine oxidation polymorphism

1 reference

12 December 2020

Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies

1 reference

12 December 2020

Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man

1 reference

12 December 2020

10.2165/00003088-199018030-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

25 August 2017

1009377721

0 references

1 reference